Analysts Issue Forecasts for COGT Q1 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Cogent Biosciences in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the technology company will post earnings of ($0.57) per share for the quarter. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.55) EPS and FY2027 earnings at $0.72 EPS.

A number of other research analysts have also recently weighed in on the company. HC Wainwright lowered their price objective on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. JPMorgan Chase & Co. lifted their price objective on Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Wedbush reaffirmed a “neutral” rating and set a $11.00 price objective on shares of Cogent Biosciences in a research report on Monday, January 13th. Finally, Needham & Company LLC cut Cogent Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Cogent Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Cogent Biosciences Stock Down 4.7 %

COGT stock opened at $8.74 on Friday. Cogent Biosciences has a twelve month low of $5.37 and a twelve month high of $12.61. The stock has a market cap of $965.42 million, a P/E ratio of -3.52 and a beta of 1.77. The business’s 50-day moving average price is $8.42 and its 200-day moving average price is $9.67.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings results on Tuesday, November 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). During the same quarter last year, the company posted ($0.64) earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in COGT. SG Americas Securities LLC increased its stake in Cogent Biosciences by 2,865.3% in the 4th quarter. SG Americas Securities LLC now owns 964,712 shares of the technology company’s stock worth $7,525,000 after acquiring an additional 932,179 shares during the last quarter. FMR LLC increased its stake in Cogent Biosciences by 8.1% in the 3rd quarter. FMR LLC now owns 8,319,411 shares of the technology company’s stock worth $89,850,000 after acquiring an additional 625,743 shares during the last quarter. Walleye Capital LLC bought a new stake in Cogent Biosciences in the 3rd quarter worth approximately $6,019,000. Geode Capital Management LLC increased its stake in Cogent Biosciences by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,280,793 shares of the technology company’s stock worth $24,638,000 after acquiring an additional 300,062 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in Cogent Biosciences in the 3rd quarter worth approximately $3,135,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.